Sugi Predict

Sugi Predict / Compounds / SCHEMBL2833540

SCHEMBL2833540

SCHEMBL2833540

CCCCCCCCC(CC(C)C)C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIK1 P39086 2/20 0.68
▸ GRIK2 Q13002 2/20 0.68
▸ SLC1A2 P43004 3/20 0.65
▸ SLC1A1 P43005 2/20 0.65
▸ SLC1A3 P43003 2/20 0.56
▸ CA2 P00918 2/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ GPR84 Q9NQS5 3/20 0.53
▸ FFAR1 O14842 1/20 0.53
▸ ACE2 Q9BYF1 1/20 0.53
▸ MAPT P10636 1/20 0.52
▸ LCK P06239 1/20 0.52
▸ PPARD Q03181 1/20 0.52
▸ ZDHHC20 Q5W0Z9 1/20 0.52
▸ ZDHHC2 Q9UIJ5 1/20 0.52
▸ CHRM1 P11229 1/20 0.46
▸ AKR1A1 P14550 1/20 0.46
▸ CHRM3 P20309 1/20 0.46
▸ HTR2A P28223 1/20 0.46
▸ HTR2C P28335 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27891419 1.00 GRIK1 (0.68) GRIK1GRIK2SLC1A2SLC1A1SLC1A3
SCHEMBL2831405 1.00 GRIK1 (0.68) GRIK1GRIK2SLC1A2SLC1A1SLC1A3
SCHEMBL2833633 1.00 GRIK1 (0.68) GRIK1GRIK2SLC1A2SLC1A1SLC1A3
SCHEMBL27855529 1.00 GRIK1 (0.68) GRIK1GRIK2SLC1A2SLC1A1SLC1A3
SCHEMBL2835497 1.00 GRIK1 (0.68) GRIK1GRIK2SLC1A2SLC1A1SLC1A3
SCHEMBL2831996 1.00 GRIK1 (0.68) GRIK1GRIK2SLC1A2SLC1A1SLC1A3
SCHEMBL2831336 1.00 GRIK1 (0.68) GRIK1GRIK2SLC1A2SLC1A1SLC1A3
SCHEMBL1871699 1.00 GRIK1 (0.68) GRIK1GRIK2SLC1A2SLC1A1SLC1A3
SCHEMBL1411995 1.00 GRIK1 (0.68) GRIK1GRIK2SLC1A2SLC1A1SLC1A3
SCHEMBL6676953 1.00 GRIK1 (0.68) GRIK1GRIK2SLC1A2SLC1A1SLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246988-A1 BRUTON'S TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2024-07-25 — — US disclosed
US-20230046457-A1 BRUTON'S TYROSINE KINASE INHIBITORS BIOGEN MA INC. 2023-02-16 — — US disclosed
US-20200399283-A1 BRUTON'S TYROSINE KINASE INHIBITORS VIRACTA THERAPEUTICS, INC. 2020-12-24 — — US disclosed
US-10577374-B2 Bruton's tyrosine kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2020-03-03 — — US disclosed
EP-3461824-A1 BRUTON'S TYROSINE KINASE INHIBITORS Biogen MA Inc. (US) 2019-04-03 — — EP disclosed
EP-2473049-B1 BRUTON'S TYROSINE KINASE INHIBITORS BIOGEN MA INC (US) 2018-11-28 — — EP disclosed
US-20180065974-A1 BRUTON'S TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-03-08 — — US disclosed
CN-104755510-B Ziegler natta catalyst system of internal donor and preparation method thereof is used as comprising 1,2 phenylene diester 印度石油有限公司 2017-11-07 — — CN disclosed
US-9790229-B2 Bruton's tyrosine kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2017-10-17 — — US disclosed
US-20160376281-A1 BRUTON'S TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2016-12-29 — — US disclosed
US-9249146-B2 Bruton'S tyrosine kinase inhibitors BIOGEN MA INC. (US) 2016-02-02 — — US disclosed
US-8889614-B2 Encapsulates THE PROCTER & GAMBLE COMPANY (US) 2014-11-18 — — US disclosed
US-20140309212-A1 BRUTON'S TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2014-10-16 — — US disclosed
US-8785440-B2 Bruton's tyrosine kinase inhibitors BIOGEN IDEC MA, INC. (US) 2014-07-22 — — US disclosed
US-20120152268-A1 ENCAPSULATES PROCTER & GAMBLE COMPANY, THE 2012-06-21 — — US disclosed
US-20120157443-A1 BRUTON'S TYROSINE KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2012-06-21 — — US disclosed
WO-2010115578-A2 NOVEL COMPOUNDS SUITED AS DIESEL SUPPLEMENTS AND DIESEL SUBSTITUTES AND ROUTES FOR THEIR SYNTHESIS ETH ZURICH (CH) 2010-10-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246988-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK GRIK1 3312/4885GRIK2 3670/4885SLC1A2 4855/4885
US-20230046457-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK GRIK1 3312/4885GRIK2 3670/4885SLC1A2 4855/4885
US-20160376281-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK GRIK1 3312/4885GRIK2 3670/4885SLC1A2 4855/4885
US-20140309212-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK GRIK1 3312/4885GRIK2 3670/4885SLC1A2 4855/4885
US-20200399283-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK GRIK1 3312/4885GRIK2 3670/4885SLC1A2 4855/4885
US-20120157443-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK GRIK1 3312/4885GRIK2 3670/4885SLC1A2 4855/4885
US-10577374-B2 Bruton's tyrosine kinase inhibitors BTK, ABL1, SYK GRIK1 3312/4885GRIK2 3670/4885SLC1A2 4855/4885
US-20180065974-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK GRIK1 3312/4885GRIK2 3670/4885SLC1A2 4855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.